|
Volumn 8, Issue 6, 2002, Pages 1984-1994
|
A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer
a a b c a |
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA GALACTOSIDASE;
PROTEIN P53;
ADENOVIRUS;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
CANCER CELL;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CELL DESTRUCTION;
CONTROLLED STUDY;
DISEASE ASSOCIATION;
FEMALE;
GENE MUTATION;
GENE TARGETING;
GENE TRANSFER;
IMMUNOCOMPETENCE;
MOUSE;
MUCOSA CELL;
MUSCLE CANCER;
NONHUMAN;
PRIORITY JOURNAL;
RADIOSENSITIVITY;
SIGNAL TRANSDUCTION;
TRANSGENE;
ADENOVIRIDAE;
ANIMALS;
APOPTOSIS;
BETA-GALACTOSIDASE;
CELL DIVISION;
DISEASE MODELS, ANIMAL;
DNA PRIMERS;
FEMALE;
GENE THERAPY;
GENE TRANSFER TECHNIQUES;
GENES, P53;
GENETIC VECTORS;
HUMANS;
IN SITU NICK-END LABELING;
MICE;
MICE, INBRED C57BL;
MICE, NUDE;
MUSCLE NEOPLASMS;
MUTATION;
NEOPLASM, RESIDUAL;
POLYMERASE CHAIN REACTION;
TUMOR CELLS, CULTURED;
TUMOR SUPPRESSOR PROTEIN P53;
|
EID: 0036278655
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (3)
|
References (26)
|